Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) and CRISPR Therapeutics AG (NASDAQ:CRSP), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of the two firms.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eiger BioPharmaceuticals Inc.||11||0.00||16.90M||-3.84||0.00|
|CRISPR Therapeutics AG||49||0.00||34.37M||-3.74||0.00|
Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Eiger BioPharmaceuticals Inc. and CRISPR Therapeutics AG.
Table 2 shows us the return on equity, net margins and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Eiger BioPharmaceuticals Inc.||153,079,710.14%||-121.2%||-71.8%|
|CRISPR Therapeutics AG||69,603,078.17%||-50.9%||-39.8%|
Eiger BioPharmaceuticals Inc.’s Current Ratio and Quick Ratio are 8.2 and 8.2 respectively. The Current Ratio and Quick Ratio of its competitor CRISPR Therapeutics AG are 15.8 and 15.8 respectively. CRISPR Therapeutics AG therefore has a better chance of paying off short and long-term obligations compared to Eiger BioPharmaceuticals Inc.
Ratings and Recommendations for Eiger BioPharmaceuticals Inc. and CRISPR Therapeutics AG can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Eiger BioPharmaceuticals Inc.||0||0||0||0.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
Meanwhile, CRISPR Therapeutics AG’s average price target is $66.5, while its potential downside is -2.36%.
Insider & Institutional Ownership
Institutional investors held 76.2% of Eiger BioPharmaceuticals Inc. shares and 50% of CRISPR Therapeutics AG shares. 0.4% are Eiger BioPharmaceuticals Inc.’s share held by insiders. Competitively, insiders own roughly 2% of CRISPR Therapeutics AG’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Eiger BioPharmaceuticals Inc.||0.73%||0.64%||2.98%||-19.14%||10.15%||8.96%|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Eiger BioPharmaceuticals Inc. has weaker performance than CRISPR Therapeutics AG
CRISPR Therapeutics AG beats Eiger BioPharmaceuticals Inc. on 8 of the 10 factors.
Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.